BioVie Inc Announces Abstract Acceptance For Sunrise-Pd Study On Bezisterim In Parkinson's Disease

Published: 2026-04-14 11:50:41 ET BIVI

Published on 04/14/2026 at 11:50 am EDT

BioVie Inc. announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson?s Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18?22, 2026. The abstract, titled A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic (J. Palumbo1, C Ahlem1, C.L. Reading1, S. O?Quinn2, J. Zhang3, M. Stacy4), summarizes the initial data on patients enrolled in the SUNRISE-PD study, and will be presented as a poster during the Movement Disorders Session on Parkinson's Disease Emerging Therapeutics, on Monday, April 20, from 5:00 PM?6:00 PM CT. Topline results from the SUNRISE-PD study are expected in mid-2026.

Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NF?B, TNF-a), bezisterim may have therapeutic potential in several disease indications, including Parkinson?s disease, Long COVID, and Alzheimer?s disease. In Parkinson?s disease, BioVie has already completed a Phase 2 study that showed patients with moderate- to severe Parkinson?s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone.

Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson?s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid-2026.

For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NF?B activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026. In Alzheimer?s disease, BioVie has conducted both Phase 2 and Phase 3 trials.

Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer?s.